Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study

European Journal of Clinical Pharmacology

Volumn 68, Issue 1, 2012, Pages 55-64

  Andreassen, Trine Naalsund ^a   Eftedal, Ingrid ^a,b   Klepstad, Pål ^a,b   Davies, Andrew ^c   Bjordal, Kristin ^d   Lundström, Staffan ^e   Kaasa, Stein ^a,b   Dale, Ola ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^c ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer pain; CYP2D6 genotypes; Metabolites; Oxycodone; Pharmacodynamic; Pharmacokinetic

Indexed keywords

CYTOCHROME P450 2D6; OXYCODONE; OXYMORPHONE; SEMORPHONE;

ADULT; AGED; ARTICLE; CANCER PAIN; CANCER PATIENT; CLINICAL ARTICLE; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYP2D6 GENE; FATIGUE; FEMALE; GENE PRODUCT; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; HOMOZYGOTE; HUMAN; MALE; METABOLITE; NAUSEA; PAIN ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BIOTRANSFORMATION; CHRONIC PAIN; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; DRUG MONITORING; EUROPE; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; MORPHINANS; NEOPLASMS; OXYCODONE; OXYMORPHONE; POLYMORPHISM, GENETIC; SEVERITY OF ILLNESS INDEX;

EID: 84857045805     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1093-5     Document Type: Article

References (43)

1. World Health Organization (2010) WHO Pain ladder. http://www.who.int/ cancer/palliative/painladder/en/. Accessed March 2011
2. L Jarlbaek H Kehlet P Sjogren 2010 Det legale opioidforbrug I Danmark (The licit opioid consumption in Denmark) Ugeskrift for Laeger 172 46 3173 3178 21073831
3. K Hamunen P Paakkari E Kalso 2009 Trends in opioid consumption in the Nordic countries 2002-2006 Eur J Pain 13 9 954 962 19091608 10.1016/j.ejpain. 2008.11.006
4. Berg C, Furu K, Litleskare I, Rønning M, Sakshaug S, Selmer R, Skurtveit S, Strøm H (2010) Reseptregisteret 2005-2009. In: Rønning M (ed) Legemiddelstatistikk 2010:2. Nasjonalt folkehelseinstitutt, Nydalen
5. KA Moore V Ramcharitar B Levine D Fowler 2003 Tentative identification of novel oxycodone metabolites in human urine J Anal Toxicol 27 6 346 352 14516487 1:CAS:528:DC%2BD3sXntlKmu7Y%3D (Pubitemid 37022162)
6. Parkinson A, Ogilvie BW (2001) Biotransformation of xenobiotics. In: Klaassen CD (ed) Casarett & Doull's toxicology, vol 6. McGraw-Hill, New York, pp 133-224
7. SE Ball J Scatina J Kao GM Ferron R Fruncillo P Mayer I Weinryb M Guida PJ Hopkins N Warner J Hall 1999 Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4 Clin Pharmacol Ther 66 3 288 294 10511065 10.1016/S0009-9236(99)70037-8 1:CAS:528:DyaK1MXmsFOjtLk%3D (Pubitemid 29451761)
8. C Wandel JS Witte JM Hall CM Stein AJ Wood GR Wilkinson 2000 CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4 1B5'-promoter region polymorphism Clin Pharmacol Ther 68 1 82 91 10945319 10.1067/mcp.2000.108506 1:CAS:528: DC%2BD3cXlvVOrsL0%3D (Pubitemid 30609830)
9. O Spigset 2001 Cytokrom P-450-systemet (The cytochrome P-450 system) Tidsskr Nor Laegeforen 121 28 3296 3298 11826461 1:STN:280: DC%2BD38%2Fps1Ojuw%3D%3D (Pubitemid 33115135)
10. UM Zanger S Raimundo M Eichelbaum 2004 Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry Naunyn Schmiedebergs Arch Pharmacol 369 1 23 37 14618296 10.1007/s00210-003-0832-2 1:CAS:528: DC%2BD2cXitF2hsQ%3D%3D (Pubitemid 38161221)
11. A Foster E Mobley Z Wang 2007 Complicated pain management in a CYP450 2D6 poor metabolizer Pain Pract 7 4 352 356 17986163 10.1111/j.1533-2500.2007. 00153.x (Pubitemid 350142307)
12. PJ Jannetto NC Bratanow 2009 Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management Pharmacogenomics 10 7 1157 1167 19604091 10.2217/pgs.09.64 1:CAS:528:DC%2BD1MXos1ent7o%3D
13. K Goryachkina A Burbello S Boldueva S Babak U Bergman L Bertilsson 2008 CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction Eur J Clin Pharmacol 64 12 1163 1173 10.1007/s00228-008-0525-3 18648788 10.1007/s00228-008-0525-3 1:CAS:528:DC%2BD1cXhsVCktLrK
14. J de Leon L Dinsmore P Wedlund 2003 Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers J Clin Psychopharmacol 23 4 420 421 12920424 10.1097/01.jcp.0000085421.74359.60 (Pubitemid 36951190)
15. P Klepstad T Fladvad F Skorpen K Bjordal A Caraceni O Dale A Davies M Kloke S Lundström M Maltoni L Radbruch R Sabatowski V Sigurdardottir F Strasser PM Fayers S Kaasa 2011 The influence from genetic variability on opioid use for cancer pain: a European study of 2294 cancer pain patients Pain 152 5 1139 1145 21398039 10.1016/j.pain.2011.01.040 1:CAS:528:DC%2BC3MXkvVWntbo%3D
16. RL Daut CS Cleeland RC Flanery 1983 Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases Pain 17 2 197 210 6646795 10.1016/0304-3959(83)90143-4 1:STN:280:DyaL2c%2FmvFeqsA%3D%3D (Pubitemid 13012221)
17. MF Folstein SE Folstein PR McHugh 1975 "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 3 189 198 10.1016/0022-3956(75)90026-6 1202204 10.1016/0022-3956(75)90026-6 1:STN:280:DyaE28%2FntFKjtw%3D%3D
18. TN Tombaugh NJ McIntyre 1992 The mini-mental state examination: a comprehensive review J Am Geriatr Soc 40 9 922 935 1512391 1:STN:280: DyaK38zotFanug%3D%3D
19. JC Anthony L LeResche U Niaz MR von Korff MF Folstein 1982 Limits of the 'Mini-Mental State' as a screening test for dementia and delirium among hospital patients Psychol Med 12 2 397 408 7100362 10.1017/S0033291700046730 1:STN:280:DyaL383kvVCmsQ%3D%3D (Pubitemid 12060564)
20. DA Karnofsky WH Abelmann LF Craver JH Burchenal 1948 The use of the nitrogen mustards in the palliative treatment of carcinoma Cancer 1 4 634 656 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L
21. NK Aaronson S Ahmedzai B Bergman M Bullinger A Cull NJ Duez A Filiberti H Flechtner SB Fleishman JC de Haes 1993 The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 5 365 376 8433390 10.1093/jnci/85.5.365 1:STN:280:DyaK3s7msVarsQ%3D%3D (Pubitemid 23073154)
22. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) The EORTC QLQ C-30 Scoring Manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels
23. AS Levey KU Eckardt Y Tsukamoto A Levin J Coresh J Rossert D De Zeeuw TH Hostetter N Lameire G Eknoyan 2005 Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 67 6 2089 2100 10.1111/j.1523-1755.2005.00365.x 15882252 10.1111/j.1523-1755.2005.00365.x (Pubitemid 41623371)
24. AS Levey J Coresh T Greene J Marsh J Kusek F Van Lente Medicine 2005 Estimating glomerular filtration rate with a new equation: MDRD4 revised equation for use with IDMS-traceable serum creatinine J Am Soc Nephrol 11 Suppl F-FC142
25. TN Andreassen P Klepstad A Davies K Bjordal S Lundstrom S Kaasa O Dale 2011 Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients Eur J Clin Pharmacol 67 5 493 506 10.1007/s00228-010-0948-5 21140139 10.1007/s00228-010-0948-5 1:CAS:528:DC%2BC3MXkvVWnsrY%3D
26. R Lovlie AK Daly A Molven JR Idle VM Steen 1996 Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene FEBS Lett 392 1 30 34 8769309 10.1016/0014-5793(96)00779-X 1:CAS:528:DyaK28Xlt1Kis74%3D (Pubitemid 26268326)
27. VM Steen OA Andreassen AK Daly T Tefre AL Borresen JR Idle AK Gulbrandsen 1995 Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology Pharmacogenetics 5 4 215 223 8528268 10.1097/00008571-199508000-00005 1:CAS:528:DyaK2MXoslGrsbc%3D
28. M Hersberger J Marti-Jaun K Rentsch E Hanseler 2000 Rapid detection of the CYP2D6 3, CYP2D6 4, and CYP2D6 6 alleles by tetra-primer PCR and of the CYP2D6 5 allele by multiplex long PCR Clin Chem 46 8 Pt 1 1072 1077 10926885 1:CAS:528:DC%2BD3cXlvFWktrc%3D (Pubitemid 30643307)
29. T Stuven EU Griese HK Kroemer M Eichelbaum UM Zanger 1996 Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction Pharmacogenetics 6 5 417 421 8946473 10.1097/00008571-199610000-00005 1:STN:280:DyaK2s7gtF2mtw%3D%3D (Pubitemid 26380097)
30. PA Games JF Howell 1976 Pairwise multiple comparison procedures with unequal N's and/or variances: a Monte Carlo study J Educ Stat 1 113 125 10.2307/1164979
31. Z Šidàk 1967 Rectangular confidence region for the means of multivariate normal distributions J Am Stat Assoc 62 626 633 10.2307/2283989
32. F Mayyas P Fayers S Kaasa O Dale 2010 A systematic review of oxymorphone in the management of chronic pain J Pain Symptom Manage 39 2 296 308 10.1016/j.jpainsymman.2009.07.010 20152592 10.1016/j.jpainsymman.2009.07.010 1:CAS:528:DC%2BC3cXjsFymsLo%3D
33. B Lalovic E Kharasch C Hoffer L Risler LY Liu-Chen DD Shen 2006 Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites Clin Pharmacol Ther 79 5 461 479 16678548 10.1016/j.clpt.2006.01.009 1:CAS:528:DC%2BD28XktVegsb4%3D
34. TN Andreassen P Klepstad A Davies K Bjordal S Lundström S Kaasa O Dale 2010 Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients Eur J Clin Pharm 67 493 506 10.1007/s00228-010-0948-5 10.1007/s00228-010-0948-5
35. R Lovlie AK Daly GE Matre A Molven VM Steen 2001 Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6 35 allele in ultrarapid metabolism? Pharmacogenetics 11 1 45 55 11207030 10.1097/00008571-200102000-00006 1:CAS:528:DC%2BD3MXhtFKhu70%3D (Pubitemid 32108661)
36. ST Zwisler TP Enggaard S Mikkelsen K Brosen SH Sindrup 2010 Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia Acta Anaesthesiol Scand 54 2 232 240 10.1111/j.1399-6576.2009.02104.x 19719813 10.1111/j.1399-6576.2009.02104.x 1:CAS:528:DC%2BC3cXhvFWqsbc%3D
37. CF Samer Y Daali M Wagner G Hopfgartner CB Eap MC Rebsamen MF Rossier D Hochstrasser P Dayer JA Desmeules 2010 The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone Br J Pharmacol 160 4 907 918 10.1111/j.1476-5381.2010.00673.x 20590587 10.1111/j.1476-5381. 2010.00673.x 1:CAS:528:DC%2BC3cXpsVKntrg%3D
38. KK Lemberg TE Heiskanen M Neuvonen VK Kontinen PJ Neuvonen ML Dahl EA Kalso 2010 Does co-administration of paroxetine change oxycodone analgesia: an interaction study in chronic pain patients Scand J Pain 1 1 24 33 10.1016/j.sjpain.2009.09.003 10.1016/j.sjpain.2009.09.003
39. ST Zwisler TP Enggaard L Noehr-Jensen RS Pedersen S Mikkelsen F Nielsen K Brosen SH Sindrup 2009 The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism Basic Clin Pharmacol Toxicol 104 4 335 344 10.1111/j.1742-7843.2009.00378.x 19281600 10.1111/j.1742-7843.2009.00378.x 1:CAS:528:DC%2BD1MXnt1Cltr4%3D
40. CF Samer Y Daali M Wagner G Hopfgartner CB Eap MC Rebsamen MF Rossier D Hochstrasser P Dayer JA Desmeules 2010 Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety Br J Pharmacol 160 4 919 930 10.1111/j.1476-5381.2010.00709.x 20590588 10.1111/j.1476-5381.2010.00673.x 1:CAS:528:DC%2BC3cXpsVKntrk%3D
41. T Heiskanen KT Olkkola E Kalso 1998 Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone Clin Pharmacol Ther 64 6 603 611 9871425 10.1016/S0009-9236(98)90051-0 1:CAS:528:DyaK1MXjslWhtA%3D%3D (Pubitemid 29011380)
42. J Gronlund TI Saari NM Hagelberg PJ Neuvonen KT Olkkola K Laine 2010 Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone Br J Clin Pharmacol 70 1 78 87 10.1111/j.1365-2125.2010.03653.x 20642550 10.1111/j.1365-2125.2010.03653.x 1:CAS:528:DC%2BC3cXps1ems70%3D
43. O Kummer F Hammann C Moser O Schaller J Drewe S Krahenbuhl 2011 Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone Eur J Clin Pharmacol 67 1 63 71 10.1007/s00228-010-0893-3 20857093 10.1007/s00228-010-0893-3 1:CAS:528:DC%2BC3MXovFSm